| A6 | Isolation of SIVmac239 neutralizing antibodies with different specificities from infected rhesus macaques | E-poster | Humoral immunity (including broadly neutralizing antibodies) |
| A6 | Immunogenicity of a 2-dose human papillomavirus vaccination schedule in HIV-infected adolescents with immune reconstitution | E-poster | Humoral immunity (including broadly neutralizing antibodies) |
| A6 | Neutralizing antibody induction associated with a germline immunoglobulin gene polymorphism in rhesus macaques after neutralization-resistant SIVsmE543-3 infection | E-poster | Humoral immunity (including broadly neutralizing antibodies) |
| B14 | A novel model for triaging HIV-positive patients for high-resolution anoscopy using high-risk human papillomavirus genotyping | E-poster | Human papillomavirus |
| A17 | HIV modifies the m6A and m5C epitranscriptomic landscape of the host cell | On-demand oral abstract session | Host cellular factors and latency |
| A17 | Identifying host genetic determinants of HIV-1 reservoir markers reveals PTDSS2 and IRF7 as potential modifying factors in HIV-1 patients | Oral abstract session with live Q&A | Host cellular factors and latency |
| A17 | Role of cellular immune activation in enrichment of deleted HIV proviruses during antiretroviral therapy | E-poster | Host cellular factors and latency |
| A17 | Role of multiple NF-κB motifs in HIV-1 LTR in modulating gene expression noise and fate-switch | E-poster | Host cellular factors and latency |
| B68 | Incidence and co-factors of Mtb infection in first 2 years of life: observational follow-up of a randomized controlled trial of INH to prevent primary Mtb infection among HIV-exposed uninfected children | On-demand oral abstract session | HIV-exposed uninfected children |
| B68 | Risk of hospitalization among children who were HIV exposed and uninfected (cHEU) in Montreal, Canada | E-poster | HIV-exposed uninfected children |